Royalty Report: Drugs, Therapeutic, Pharmaceuticals – Collection: 26401


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Drugs
  • Therapeutic
  • Pharmaceuticals
  • Biotechnology
  • Cancer
  • Drug Discovery
  • Immune

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26401

License Grant
The Company hereby agrees to grant to Southern of Malaysia an exclusive Option to purchase the Master License for Malaysia, Indonesia, Philippines, Thailand, Taiwan, Korea, Singapore, Australia and New Zealand; human leukocyte-derived (natural) interferon alpha.
License Property
Interferons are proteins that modulate the activity of nearly every aspect of the immune system.  The Licensed Product is technically classified as an experimental drug until clinical trials have been completed.  Natural Interferon technology.
Field of Use
The rights granted apply to the immune system.

IPSCIO Record ID: 1774

License Grant
Licensor grants to the Scottish Licensee exclusive license, within the Exclusive Territory, European Union; human leukocyte-derived (natural) interferon alpha.
License Property
Interferons are proteins that modulate the activity of nearly every aspect of the immune system.
Field of Use
This exclusive right and license herein granted shall apply to all Proprietary Rights and Licensed
Property which the Licensor now owns or controls, or hereafter may own or control and which relate to the Licensed Property.

IPSCIO Record ID: 6729

License Grant
Licensor and Licensee entered into a License Agreement relating to Nimotuzumab.  Under this License Agreement, the Licensor exclusively Sub-Licensed to the Licensee the patent rights and related know-how for Nimotuzumab for the treatment of cancer in humans, for development, use and sale in Thailand, Singapore, Indonesia, Taiwan, Myanmar, Cambodia, Laos, Brunei, Philippines, Malaysia, African Republic of the Congo, Nigeria and South Africa.
License Property
Patents and know-how arising during the term of the Agreement are owned by the generating party. For the term of the Agreement, the Parties have agreed to grant to each other, an exclusive, fully-paid and royalty-free License to any arising intellectual property, in order to research, develop, make, have made, import, use, sell or otherwise deal in any products containing Nimotuzumab. The Licensee is responsible for the development and commercialization of Nimotuzumab in the agreed upon countries, in accordance with a written research and development plan, and for all costs in connection therewith.  
The Innogene License Agreement requires Innogene to purchase 100% of its supplies of Nimotuzumab for non-clinical and clinical studies and trials and 100% of its commercial supplies of Nimotuzumab from Licensor.

Technology 80.02.113
Improved Treatment Method for Cancer

  review at Patent Office    
  review at Patent Office    

Technology 80.02.194
of Treatment of Hormone-Unresponsive Metastatic Prostate Cancer
  Natl. Phase    

Field of Use
The rights granted apply to the healthcare industry relating to cancer in humans.

IPSCIO Record ID: 26428

License Grant
The Company hereby grants to the Licensee of the United Kingdom an exclusive license to make, have made, use and sell Product(s). Invention means patented and unpatented, patentable and un-patentable, proprietary technology related to a 2’-fluoro-2-halo substituted purine nucleoside (hereafter Technology) developed by or on behalf of SRI, that is (i) related to human health applications of the Technology or (ii) necessary for the practice of Technology for human health applications as disclosed and claimed in the Patent(s).
License Property
The agreement is to co-develop the purine-based nucleoside technology that may be effective in the treatment of leukemia and lymphoma.  The lead compound of such purine-based nucleosides is known as clofarabine.

The Product(s) are Drugs effective against hematologic malignancies and solid tumors as well as other therapeutic indications, such as (but not exclusively) skin disorders and transplantation immunity. All modes of administration, particularly oral and iv., are included in these terms as are specialized formulations such as those imparting controlled-release characteristics.

Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 26640

License Grant
Japanese Licensor hereby grants an exclusive licence to Canadian Licensee to market and produce the Products.
License Property
The Products shall comprise, but not be limited to, the following
·Recombinant Human Interferon alpha-2a (rHulFN-a 2a) and alpha-2b (rHulFN-a 2b)
·Recombinant Human granulocyte colony stimulating factor (rHuG-CSF);
·Recombinant Human granulocyte macrophage colony stimulating factor (rHuGM-CSF);
·Interleukin 2
·EPO (erythropoietin)

The Company has acquired license to patented technologies related to the production of therapeutic proteins, alpha and beta interferon, Interleukin 2, EPO (erythropoietin) and human growth factors (rHuG-CSF and rHuGM-CSF).

Field of Use
Field of Use relates to the medical industry.

IPSCIO Record ID: 267745

License Grant
The Company granted to Chinese Licensee an exclusive license to develop and commercialize the antibody-drug conjugate IMMU-132 (sacituzumab govitecan) (the Product) in the People’s Republic of China, Taiwan, Hong Kong, Macao, Indonesia, Philippines, Vietnam, Thailand, South Korea, Malaysia, Singapore and Mongolia.
License Property
The product ,IMMU-132 (sacituzumab govitecan), relates to a metastatic triple negative breast cancer indication for patients who have received at least 2 prior anti-cancer therapies in a metastatic setting.
Field of Use
This agreement pertains to the drug industry

IPSCIO Record ID: 27625

License Grant
The Licensee obtained a non-exclusive perpetual License from the Licensor that grants worldwide rights to make, use, and sell, any formulation of Natural Alpha Interferon. The Agreement permits the Licensee to grant marketing rights with respect to Natural Alpha Interferon products to third parties, excluding injectable products, in any country in which Licensor has patent rights, to any third party not listed on a schedule of approximately 50 potential marketing partners without the consent of the Licensor.
License Property
The Licensor has been issued patents covering human alpha interferon in many countries throughout the world.
Field of Use
Natural alpha interferon is composed of a family of proteins containing many molecular species of interferon.

Alfa-interferon, or interferon, is a protein that increases lymphocyte (white blood cell) activity to help clear HCV from the blood and liver. Interferon fights the formation of scar tissue in the liver and has been shown to prolong an individual's life, thus preventing or delaying the need for liver transplantation.

IPSCIO Record ID: 245923

License Grant
With this amendment Licensor and Japanese Licensee desire to add and include their cooperative research relationship to develop and market novel therapeutic products whose action is based upon the regulation of STATs involved in IL-18, except to the extent such activation occurs through a protein that is also active within the IL-1 pathway function.

In the agreement, the parties previously entered into, the Collaboration Agreement which, established a cooperative research and development relationship in order to discover, develop and market novel products whose action is based upon the regulation of Signal Transducers and Activators of Transcription ('STATs') involved in [IL-4, IL-12 and gamma interferon] functions.

In the original agreement, the Licensor grants the Japanese Licensee
– an exclusive license to make, have made, use, offer to sell, sell and import Product in the Licensee Territory under the Licensor Technology; and
– a nonexclusive,  worldwide license under Licensors rights in and to the Program Know-How and Program Patents for any purpose outside the Field.

License Property
Licensor is engaged in the research and development of therapeutic pharmaceutical products based upon the regulation of transcription factors.

With the amendment, the compound is updated and shall mean a substance which is identified by the Parties during the term of the Research Program as either inhibiting or promoting the activity of STATs activated by IL-4, IL-12, gamma interferon or IL-18, except to the extent such activation occurs through a protein that is also active within the IL-1 pathway.

Product shall mean a Drug Candidate, when used as an active ingredient in a pharmaceutical product for use in the Field, including all indications, formulations, line extension or modes of administration thereof.

Field of Use
The Field shall mean the therapeutic modulation of human immune function where use is initially restricted to prescription use, whether or not such restriction to prescription use continues.

Licensor have discovered two human transcription factors, STAT6 and STAT4, that are key proteins involved in immune regulation. When overstimulated, these proteins are instrumental in the development of allergy and asthma in the case of STAT6, and in the development of autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease in the case of STAT4.  Experiments in animals have demonstrated that disabling these proteins is safe and blocks inappropriate immune responses. These results demonstrate that STAT6 and STAT4 are excellent drug discovery targets.  The goal is to discover drugs capable of selectively blocking STAT6 or STAT4 function.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.